Expanding Orthopedics Inc. has obtained FDA Clearance for its FLXfit?, the world's first 3D expandable interbody cage - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Expanding Orthopedics Inc. has obtained FDA Clearance for its FLXfit?, the world's first 3D expandable interbody cage EOI announces FDA Clearance of the FLXfit", the only TLIF cage combining articulation and height expansion with lordotic angle correction.


Expanding Orthopedics Inc. has obtained FDA Clearance for its FLXfit™, the world's first 3D expandable interbody cage

EOI announces FDA Clearance of the FLXfit™, the only TLIF cage combining articulation and height expansion with lordotic angle correction.

PR Newswire

OR AKIVA, Israel, July 21, 2014 /PRNewswire/ -- Expanding Orthopedics Inc. (EOI), a privately held medical device company focused on developing and commercializing innovative expandable devices for spine surgeries, is excited to announce that its FLXfit™, the world's first 3D expandable interbody cage, is cleared for commercialization in the US.

FLXfit(TM) 3D expandable interbody cage

Ofer Bokobza, CEO of Expanding Orthopedics, said that "I am extremely proud of the EOI team and our KOLs worldwide enabling us to reach this significant milestone. The FLXfit™ is the first TLIF cage available worldwide with the 3D expansion capability. This unique and patented technology combines minimal invasive access, maximum footprint support and large bone graft chamber with unique lordotic expansion for sagittal balance correction."

Dr. Hansen Yuan, a worldwide recognized spine surgeon and one of the leading industry experts as well as a Director at EOI explained that "I don't know of any other cage commercially available in the US combining this many critical and beneficial features as the FLXfit™. Minimal invasive through a single, small port, self-steering articulation for optimal placement, large footprint for best stability and a large plate to plate bone graft chamber for solid bone fusion." Additionally, Dr. Yuan explained that the "real revolution of the FLXfit™ is the combination of these features with the unique lordotic expansion technology which enables an optimal press fit while restoring the anatomy of the spine and lordotic angle correction." He added that "the FLXfit™ has the potential to change the way spine surgeons treat their patients today."

Mr. Bokobza stated "EOI is already in the process of signing distribution agreements with leading US spine distributors and I expect the FLXfit™ to quickly become a significant player in the  fast growing expandable cage's segment based on its unique capabilities. This segment shows a steady 30% CAGR with an established reimbursement codes."

Mr. Bokobza, concluded "as part of our continuous strive to improve spine's standard of care, the EOI's team together with its distinguished advisors is going to execute on our product pipeline and deliver a complete family of expandable cages based our expanding devices IP Platform. The expanding cages' product family, coupled with the CE Marked XPED™ Expandable Pedicle Screw System, will reinforce our position as a leading company delivering innovative expanding devices and strengthen our vision as a driver for continuous improvement in spine care solutions."

About Expanding Orthopedics Inc.
Expanding Orthopedics Inc. is medical device company developing and marketing innovative products designed to address unmet clinical needs for spine care and improve long-term patients' outcome. The Company is spearheaded by seasoned management team, and is backed by prominent spine surgeons. EOI owns a broad patent portfolio around anatomically fit, expandable devices for enhanced stability through a minimally invasive approach.

Contact info:
David Elkaim, VP Marketing and Sales
E-mail: david@xortho.com 

Photo - http://photos.prnewswire.com/prnh/20140721/128793

SOURCE Expanding Orthopedics Inc.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here